| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10916866 | Pathology - Research and Practice | 2014 | 6 Pages |
Abstract
Patients with ERCC1-negative tumors show a benefit from neoadjuvant chemoradiation, ERCC1 expression and tumor regression are useful predictive markers in patients with locally advanced operable ESCC receiving neoadjuvant chemoradiation followed by surgery.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Hong Ge, Yufei Lu, Yongshun Chen, Xiaoli Zheng, Wen Wang, Jinming Yu,